1998
Increased Levels of Advanced Glycation Endproducts in the Lenses and Blood Vessels of Cigarette Smokers
Nicholl I, Stitt A, Moore J, Ritchie A, Archer D, Bucala R. Increased Levels of Advanced Glycation Endproducts in the Lenses and Blood Vessels of Cigarette Smokers. Molecular Medicine 1998, 4: 594-601. PMID: 9848076, PMCID: PMC2230315, DOI: 10.1007/bf03401759.Peer-Reviewed Original ResearchConceptsNondiabetic smokersTissues of smokersCoronary arteryGlycation endproductsSingle greatest preventable causeGreatest preventable causeEnd-organ complicationsAnti-AGE antibodyConsequence of diabetesAdvanced glycation endproductsRenal insufficiencyCigarette smokersPreventable causeSmokersCigarette smokeHigh levelsCausal associationNonsmokersDiabetesMainstream cigarette smokeBlood vesselsAgeExtracellular matrix proteinsArteryLens fiber cells
1997
Tobacco smoke is a source of toxic reactive glycation products
Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R, Cerami A. Tobacco smoke is a source of toxic reactive glycation products. Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 13915-13920. PMID: 9391127, PMCID: PMC28407, DOI: 10.1073/pnas.94.25.13915.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsTobacco smokeGlycation productsAGE formationSerum AGE levelsIncidence of atherosclerosisPlasma of patientsGlycation end productsRenal insufficiencyCerebrovascular diseaseCigarette smokersHuman smokersHigh prevalenceHigh riskSmokersNonsmokersGlycotoxinsPatientsSpecific fluorescenceSerum proteinsDiseaseCuring of tobaccoAqueous extractSmokeTobaccoReduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia
Fishbane S, Bucala R, Pereira B, Founds H, Vlassara H. Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. Kidney International 1997, 52: 1645-1650. PMID: 9407512, DOI: 10.1038/ki.1997.497.Peer-Reviewed Original ResearchConceptsAdvanced glycation endoproductsLow density lipoprotein clearanceLong-term hemodialysis therapyRenal replacement treatmentEffect of hemodialysisAGE removalDiabetic ESRDSerum apoBESRD patientsRenal insufficiencyClinical outcomesLipoprotein clearancePlasma apoBHemodialysis therapyReplacement treatmentApoliprotein BPatientsGroup subjectsHemodialysis filtersReactive substancesApoBPlasma apolipoproteinsAGE clearanceBaselineClearance
1996
Site-specific modification of apolipoprotein B by advanced glycosylation end-products: implications for lipoprotein clearance and atherogenesis
Bucala R. Site-specific modification of apolipoprotein B by advanced glycosylation end-products: implications for lipoprotein clearance and atherogenesis. Nephrology Dialysis Transplantation 1996, 11: 17-19. PMID: 9044301, DOI: 10.1093/ndt/11.supp5.17.Peer-Reviewed Original ResearchConceptsLDL receptorAGE modificationApolipoprotein BAdvanced glycosylationHuman fibroblast LDL receptorsAGE-modified formAGE-specific antibodiesRegion of apoBNon-diabetic individualsFibroblast LDL receptorLDL receptor binding siteRenal insufficiencyDiabetes mellitusDiabetic patientsElevated LDLAGE-LDLLipoprotein clearanceReceptor binding sitesHuman LDL receptorGeneral populationPlasma clearance kineticsTransgenic miceLDLAGE formationClearance kinetics
1995
Identification of the Major Site of Apolipoprotein B Modification by Advanced Glycosylation End Products Blocking Uptake by the Low Density Lipoprotein Receptor *
Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the Major Site of Apolipoprotein B Modification by Advanced Glycosylation End Products Blocking Uptake by the Low Density Lipoprotein Receptor *. Journal Of Biological Chemistry 1995, 270: 10828-10832. PMID: 7738020, DOI: 10.1074/jbc.270.18.10828.Peer-Reviewed Original ResearchConceptsLow-density lipoproteinAGE-modified formAdvanced glycosylation end productsLDL receptorApolipoprotein BHuman fibroblast LDL receptorsAGE-specific antibodiesApolipoprotein B modificationDiabetic vascular diseaseLow-density lipoprotein receptorGlycosylation end productsDensity lipoprotein receptorFibroblast LDL receptorMajor siteAGE immunoreactivityRenal insufficiencyGlucose-derived Amadori productsVascular diseasePlasma clearance kineticsDensity lipoproteinLipoprotein receptorAGE formationClearance kineticsAGE modificationPredominant site